EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 16th, 2015 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and entered into as of the 25th day of September, 2015 (the “Effective Date”) by and between LA Cell, Inc., a Delaware corporation with a principal place of business at 9380 Judicial Drive, San Diego, CA 92121 (“Licensee”) and City of Hope, a California nonprofit public benefit corporation located at 1500 East Duarte Road, Duarte, California 91010 (“City of Hope” or “COH”). Licensee and COH are each sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
MEMBERSHIP INTEREST PURCHASE AGREEMENTMembership Interest Purchase Agreement • November 16th, 2015 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
This Membership Interest Purchase Agreement is made and entered into as of August 7, 2015, by and among TNK Therapeutics, Inc., a Delaware corporation (the “Purchaser”), CARgenix Holdings LLC, a Rhode Island and Providence Plantations limited liability company (the “Company”), the members of the Company set forth on the signature pages to this Agreement (collectively, the “Members” and, individually, a “Member”), Jaymin Patel, an individual resident of Rhode Island, as representative of the Members pursuant to Article X (the “Members’ Representative”), and, solely with respect to Sections 1.4, 1.6 and 1.7 and Article XI, Sorrento Therapeutics Inc., a Delaware corporation (“Sorrento”).
STOCK PURCHASE AGREEMENTStock Purchase Agreement • November 16th, 2015 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
THIS STOCK PURCHASE AGREEMENT is made and entered into as of August 7, 2015, by and among TNK Therapeutics, Inc., a Delaware corporation (the “Purchaser”), BDL Products, Inc., a Delaware corporation (the “Company”), the stockholders of the Company set forth on the signature pages to this Agreement (collectively, the “Stockholders” and, individually, a “Stockholder”), Richard P. Junghans, M.D., Ph.D., an individual resident of 1 Lyndboro Place, Boston, Massachusetts 02116 , as representative of the Stockholders pursuant to Article XI (the “Stockholders’ Representative”), and, solely with respect to Sections 1.6 and 1.7 and Article XII, Sorrento Therapeutics Inc., a Delaware corporation (“Sorrento”).
BINDING TERM SHEET FOR LICENSE BETWEEN CYTOLUMINA/FETOLUMINA AND TNK THERAPEUTICSLicense Agreement • November 16th, 2015 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
IN WITNESS WHEREOF, the Parties hereto have executed this Term Sheet by their duly authorized representatives, effective as of July 27, 2015 (the “Effective Date”).
